View in EDS

Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.

Saved in:

Bibliographic Details
Title:	Long-Term Safety and Efficacy of Dupilumab Treatment in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
Authors:	Paller AS; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.; Division of Dermatology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA., Pinter A; Department of Dermatology, University Hospital Frankfurt am Main, Frankfurt am Main, Germany., Wine Lee L; Dermatology and Dermatologic Surgery, Medical University of South Carolina, Charleston, SC, USA., Aschoff R; University Hospital Carl Gustav Carus, Dresden, Germany., Zdybski J; Klinika Zdybski Dermedic, Ostrowiec Świętokrzyski, Poland., Schnopp C; Department of Dermatology and Allergology, Technical University of Munich, Munich, Germany., Khokhar FA; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Praestgaard AH; Sanofi, Cambridge, MA, USA., Bansal A; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Shumel B; Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA., Bastian M; Sanofi, Frankfurt, Germany. mike_bastian@gmx.net.
Source:	Paediatric drugs [Paediatr Drugs] 2026 May; Vol. 28 (3), pp. 307-320. Date of Electronic Publication: 2026 Apr 02.
Publication Type:	Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info:	Publisher: Springer International Country of Publication: Switzerland NLM ID: 100883685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-2019 (Electronic) Linking ISSN: 11745878 NLM ISO Abbreviation: Paediatr Drugs Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1179-2019
DOI:	10.1007/s40272-026-00747-4